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Background: Early failure (within 6 weeks of construction) of prosthetic arteriovenous access (AVA) is traditionally treated by
surgical revision rather than endovascular intervention because it is assumed to be related to technical factors related to the
surgery. This premise is not evidence based and our results for surgical thrombectomy have been poor. Based on our previous
experience with angiography and thrombolysis in newly constructed autogenous AVAs, we changed our approach to perform
endovascular thrombolysis initially, instead of proceeding directly to surgical revision.
Methods: We prospectively studied all patients who had an early failure of new prosthetic AVA from January 2000 to June
2004 to determine the cause of and treat the occlusions by endovascular means. Thrombolysis took place at least 7 days
after surgery, allowing sufficient tissue incorporation to prevent puncture site bleeding. No patients were excluded from
the study.
Results: During the 54 months of the study, 269 prosthetic AVAs were constructed at our center. Twenty patients had early
occlusion. The mean time from creation of the prosthetic AVA to occlusion was 15.8  10.9 (median 13, range 3-41) days and
the mean time to intervention was 25.0  11.6 (median 21, range 9-54) days. Of the 20 patients, 17 underwent successful
endovascular thrombolysis. The only patient of the 20 found to have a technical problem related to surgery had this resolved
angiographically. There was one complication in a patient with failed endovascular thrombolysis, who had extravasation from
the arterial anastomosis that halted the procedure. This patient later had surgical revision in keeping with the angiographic
findings. Cumulative patency rates at 6 months and 1 year were 75% and 68%, respectively.
Conclusions: Endovascular thrombolysis for early occlusion of prosthetic AVAs is feasible, safe, and is associated with a
good patency rate. It appears to be a better initial approach than surgical revision in these patients because technical-
surgical problems related to AVA construction are rare. ( J Vasc Surg 2008;47:585-90.)Arteriovenous access (AVA) for hemodialysis has been the
mainstay of survival for patients with end-stage renal disease
(ESRD) ever since publication of the landmark article by
Brescia, Cimino, Eppel, and Hurwitz that first introduced this
treatment.1 Autogenous AVA is the preferred access for he-
modialysis2 and a high rate of construction of autogenous
AVAs can be achieved in the appropriate setting.3 However,
the creation of an autogenous AVA is not feasible in a signif-
icant number of patients, and prosthetic AVA is then the
accepted alternative to autogenous AVA and is widely used for
this purpose. The creation of prosthetic AVAs using expanded
polytetrafluoroethylene (ePTFE) is technically simple, short-
term results are usually good, and a high rate of long-term
patency can be achieved with aggressive follow-up and inter-
ventional therapy.4 Preoperative venous and arterial mapping
and planning of the access procedure have contributed to
minimizing failure rates in the setting of a vascular access
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prosthetic AVAs remains a problem.
Early thrombosis of prosthetic AVAs (within 6 weeks of
surgery) is traditionally attributed to technical factors re-
lated to the surgery and is therefore treated by surgical
revision rather than endovascular intervention.5 In our
center, the results of surgical thrombectomy for early fail-
ure have been unsatisfactory even though technical prob-
lems could be diagnosed only rarely in most patients.
Endovascular thrombolysis is the treatment of choice for
thrombosis of well incorporated functioning prosthetic
AVAs, with a 75% to 94% immediate success rate.6 For early
thrombosis, however, graft incorporation may not be ade-
quate for safe angiography via the newly constructed access
and might cause significant hemorrhagic complications.
Evidence to support the premise that technical factors
related to the surgery are responsible for early thrombosis is
lacking and our own results in these situations have been
unsatisfactory. Based on our good experience with endo-
vascular and thrombolytic therapy of newly constructed
autogenous AVAs, we decided to use endovascular throm-
bolysis initially instead of proceeding directly to surgical
revision. The limiting factor of graft incorporation was
addressed by carrying out the thrombolytic therapy at least
7 to 10 days postoperatively.
METHODS
We prospectively studied all patients who had an occlu-
sion of a prosthetic AVA within 6 weeks of new fistula
creation (early occlusion) from January 2000 to June 2004.
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of the prosthetic AVA was planned according to the avail-
ability of blood vessels and the previous occurrence of
fistula surgery. Doppler-assessed blood pressure was mea-
sured in both brachial arteries. The brachial, radial, and
ulnar arteries were carefully assessed by Doppler ultrasound
(Acuson SEQUOIA 512, Mountain View, Calif), with a
6L3 multifrequency linear array transducer, for minimal
diameter, degree of calcification, and to rule out proximal
arterial stenosis.
Meticulous mapping by doppler ultra sonography of
the cephalic and basilic veins from the wrist to the axillary
and subclavian veins was done after application of a high
arm venous tourniquet inflated to 50 mm Hg and 2 min-
utes of vigorous hand exercise to engorge the veins. For
autogenous AVA, a minimal venous diameter of 2.5 mm is
accepted, avoiding areas with segmental stenoses. Multiple
segmental stenoses will contraindicate the use of that spe-
cific vein. Prosthetic AVAs were constructed only if no vein
was found to be available for use in autogenous AVA.
Minimal vein diameter for attachment of prosthetic AVA was
3.5 cm. Collateral vessels were never used for AVA con-
struction. Patients who were unsuitable for autogenous
accesses had prosthetic AVAs placed shortly before dialysis
in preference to central lines and not as preemptive grafts
some time before dialysis was started.
Doppler traces or pressures indicating proximal disease
resulted in additional noninvasive studies. Preoperative
venography was also indicated for patients with pacemakers
or who had long-term or multiple central venous catheter-
izations. Regional anesthesia using a supraclavicular bra-
chial plexus block was favored as the anesthetic tech-
nique.7,8
The preferred method of prosthetic AVA creation was
the forearm loop using tapered 4-7 mm stretch ePTFE
(Gore-Tex, W.I. Gore Associates, Inc, Flagstaff, Ariz). The
4-mm arterial end of the graft was anastomosed to the
brachial artery in the cubital fossa and the 7-mm venous
end was anastomosed to a cubital vein or the basilic vein
above the elbow if vein diameter was suitable. In patients
with previous fistula construction in the forearm, with no
prospect for any additional forearm prosthetic AVA con-
struction, a C-shaped graft was placed in the upper arm
with anastomoses to the brachial artery above the elbow
and to the basilic or brachial vein in the axilla. In patients
with bilateral central vein occlusion, prosthetic AVAs were
constructed in the thigh.
Follow-up protocols. Within the framework of our
surveillance program all patients came to our clinic 10 days
postoperatively for a first checkup and suture removal.
Doppler ultrasound was performed at the time of suture
removal if there were clinical signs suggesting that the
access was failing, otherwise patients were scheduled for
Doppler ultrasound examination 1 month postoperatively
as part of our regular surveillance protocol.3 Some patients
with occlusion were diagnosed earlier in their respective
dialysis units. Those patients who were found to have
failing prosthetic AVAs based on the clinical and Dopplerultrasound examination at suture removal, or if the occlu-
sion had been diagnosed in the nephrology unit before
suture removal, were referred to have thrombolysis at least
7 days postoperatively. In most of the patients, the AVA
was patent at the time of removal of sutures and dialysis.
Staff was instructed regarding the timing of first venipuc-
ture, which usually took place 2 to 4 weeks postoperatively.
If the diagnosis of thrombosis was made later than the third
week, thrombolytic therapy was scheduled as soon as pos-
sible regardless of whether they had had a first cannulation
and dialysis.
Interventions. When occlusion occurred, Doppler ul-
trasound alone was performed if the occlusion occurred in
the first week postoperatively, or angiography was done
immediately with the diagnosis of occlusion if it occurred
more than 1 week postoperatively. If a salvageable anatom-
ical situation was revealed, endovascular angiographic
chemical or mechanical thrombolytic therapy was insti-
tuted.
For chemical thrombolysis a 17G infusion catheter (BD
Venflon, Helsingborg, Sweden) was inserted at a point
close to the arch of the graft in the direction of the venous
anastomosis. An 8 ml solution containing 250,000 units of
urokinase, 5000 units of heparin and saline was slowly
injected while gently massaging the graft to spread the
solution through the clot and intermittently obstructing
the venous limb to aid penetration of the arterial limb. The
solution was left in-situ for approximately 45 to 60 min-
utes. Thereafter the venous catheter was exchanged for a 6F
sidearm sheath (Cook, Check Flo introducer, Blooming-
ton, Ind) in the interventional radiology suite. A pullback
diagnostic angiogram demonstrating the outflow tract
from the SVC to the venous anastamosis was performed to
identify possible anatomical problems, and if present, ste-
noses were treated with balloon angioplasty. The venous
anastomosis was dilated up to a diameter of 7 mm to match
the size of the venous end of the graft to fragment any clot
that may adhere to the anastomsis, and residual thrombus
was evacuated from the graft. A second 6F introducer
sheath (Cordis Brite tip sheath, Miami, Fla) was placed and
directed to the arterial anastamosis. Removal of the arterial
platelet plug at the arterial anastomosis was carried out with
an over-the-wire Fogarty Catheter (Edwards Life Sciences,
Irvine, Calif) that enabled the return of arterial blood flow
and thereafter angioplasty was performed if necessary.
After a good clinical thrill was detected, the sheaths
were removed and the entrance sites closed with purse
string or figure of eight sutures (vicryl 3-0 Ethicon, John-
son & Johnson International, Dilbeek, Belgium). These
were removed after 24 hours at the treating dialysis centre.
Mechanical thrombectomy followed a similar routine,
using the percutaneous Arrow-Trerotola device (Arrow
International, Reading, Pa) but without the necessity for
using a Fogarty balloon catheter. In the initial period of the
study, we preferred the use of a mechanical device over
urokinase because of the theoretical risk of bleeding, but
after gaining some experience with chemical thrombolysis,
urokinase infusion was used first, and combined with a
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clots.
All endovascular and surgical interventions were carried
out as ambulatory procedures.
Exclusions. No patients were excluded from the
study.
Outcomes and statistical analysis. Separate charts
were kept (in addition to hospital files) for each patient in
the study group comprising all Doppler ultrasound exami-
nations, operation notes, invasive radiology reports, and
follow-up data.
In keeping with accepted radiological criteria, throm-
bolysis was considered to have been successful if the patient
had at least one successful dialysis session after thromboly-
sis.9 Cumulative patency was calculated for the patients in
the study and was defined as the interval from the time of
access placement until access abandonment, including re-
establishment of adequate patency in the same prosthetic
AVA after revision of occlusions by surgery or angio-
plasty.6,10
Analysis of results was carried out by the life table
analysis method.10-12 Means were expressed as mean 
standard deviation. Graphs were constructed using Graph-
Pad Prism v3.02, 2000.
RESULTS
During the period from January 2000 to June 2004,
850 AVAs for new hemodialysis access were constructed, of
which 269 (32%) were prosthetic AVAs. Twenty (7%) of
the 269 prosthetic AVAs occluded at 6 weeks or less, and
these patients constitute the study group. Nineteen were
upper limb AVAs and only one was a lower limb (thigh)
access. No immediate peri-graft hematomas were noted.
The mean time from creation of the prosthetic AVA to
occlusion was 15.8  10.9 (median 13, range 3-41) days
and the mean time to intervention was 25.0  11.6 (me-
dian 21, range 9-54) days from creation of the AVAs. The
patients and the procedures carried out are described in
Table I. Characteristics of 20 patients with early
occlusion (6 weeks) after prosthetic arteriovenous
access surgery
Females 14 (70%)
Related condition
Diabetes mellitus 8 (40%)
Hypercoagulable state 4 (20%)
-Protein C deficiency
-Systemic lupus erythematosus
-Factor V Leiden
-Rheumatoid arthritis
Low blood pressure 1
Central vein catheter* 9
Type of treatment
Trerotola PTD 6
Urokinase 12
Combined 2
PTD, Percutaneous thrombectomy device.
*There was one additional central catheter in the femoral vein.Table I. Four patients had hypercoagulable states includingone each of protein C deficiency, systemic lupus erythem-
atosus (SLE), factor V Leiden, and rheumatoid arthritis
(which, although not in itself a hypercoagulable state, is
associated with hypercoagulability). Coagulation problems
were undiagnosed before occlusion in the patients with
protein C deficiency and factor V Leiden. Ten patients had
indwelling central venous catheters (nine were internal
jugular and one was a femoral catheter), and one patient
had chronically low blood pressure. Of the 20 patients, six
had thrombectomy with a mechanical device only, 12 re-
ceived urokinase only, and two had chemical thrombolysis
combined with mechanical device thrombectomy that was
added to the procedure in order to clear adherent clots.
In nineteen of the prosthetic AVAs, no surgery-related
technical cause for occlusion was found on angiography.
Technical problems related to the access surgery were
found in one patient only. He had a severe stenosis at the
venous anastomosis, probably caused by valve suturing in
the anastomotic suture line, which was easily dilated angio-
graphically by transluminal angioplasty (Table II).
Ten (50%) of the patients had proximal vein stenosis, or
central vein stenosis or occlusion, or both (Table II). In two
patients, one with systemic lupus erythematosus and the
other with rheumatoid arthritis, complete central vein oc-
clusion occurred due to recent (one in the month prior to
access construction and the other 10 days before the sur-
gery) insertion of central vein catheter. The other eight
patients had treatable lesions that were probably missed
because of inadequate preoperative imaging. In five pa-
tients, a proximal draining vein stenosis 50% was identi-
fied: two in themedian cubital vein junction with the basilic
vein (with venous anastomosis to the median cubital vein),
two in the proximal basilic vein (anastomosis to the basilic
vein above the elbow), and one in the proximal cephalic
vein (10 cm above the anastomosis to the cephalic vein).
Five patients had central vein stenosis (50%) or occlusion,
three in the innominate vein and two in the subclavian vein.
Three patients had both proximal vein and central vein
stenosis or occlusion. Occlusions and stenoses that were
not in the graft itself were also treated by angioplasty with
Table II. Angiographic findings for the access and
vasculature in 20 patients with early occlusion (6 weeks)
after prosthetic arteriovenous access
Normal graft appearance 19
No angiographic findings 9
Proximal vein stenosis (50%)* 5
Central vein stenosis (50%) or occlusion*,
†
5
Subclavian, 2
Innominate, 3
Technical (venous anastomosis stenosis due to
vein valve suture) 1
Total 20
*Three combined proximal and central vein stenoses or occlusions.
†Two catheter related occlusions (see text).or without stenting.
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graft and vasculature on angiography with no discernible
anatomical cause for the occlusion (Table II).
Ten patients had a central vein catheter in place at the
time of thrombolysis, nine of them in patients with upper
arm AVAs and one with a thigh AVA. Five of the nine
central vein catheters in patients with upper arm AVAs were
on the ipsilateral side: in two patients, there was a complete
central vein occlusion, one in the subclavian vein and one in
the innominate vein, both on the side of the AVA; another
had a 50% stenosis at the innominate vein; the other two
had no central vein stenosis.
Thrombolysis was unsuccessful in three patients. Minor
extravasation at the arterial anastomosis caused the proce-
dure to be halted in one case. There were two patients with
immediate thrombolysis failures due to central vein occlu-
sion that thrombosed repeatedly on the angiography table,
presumably because of their hypercoagulability and in spite
of the addition of further doses of heparin (one with SLE
and the other with rheumatoid arthritis), even though a
good anatomical result in the graft and the central veins was
achieved in both patients. Seventeen other patients (85%)
had successful thrombolysis.
In the patient with failed endovascular thrombolysis,
extravasation occurred at the time of arterial thrombectomy
followed by angioplasty, which caused the procedure to be
halted. This was a complication of the endovascular proce-
dures and was unrelated to any technical surgical problem
related to the AVA construction. This patient had surgical
thrombectomy and revision in accordance with the angio-
graphic findings (that showed a proximal median cubital
vein stenosis) with a jump graft to the basilic vein, which
also failed. This graft was abandoned and a new access was
constructed. There were no other complications. There was
no clinical evidence of pulmonary emboli that might result
from the thrombolysis or the gentle massaging of the clots.
In the two patients with a hypercoagulable state and central
vein occlusion, new AVAs were created in the contralateral
arm, and the patients were anticoagulated with warfarin.
The cumulative patency rates at 6 months and 1 year
were 75% and 68%, respectively (Fig, Appendix, online
only). In the 20 patients with early prosthetic AVA occlu-
sion described here, 14 additional interventions were re-
quired to maintain patency during the 24-month follow-up
period.
DISCUSSION
Patent vascular access is essential for the treatment and
survival of ESRD patients. Autogenous AVA is preferred as
the access for hemodialysis, being more durable and having
a lower complication rate than prosthetic AVA. The cre-
ation of a prosthetic AVA for hemodialysis should be carried
out only in patients in whom it is found that the creation of an
autogenous AVA is not possible.1,2 Preoperative assessment
with color-coded Doppler ultrasonography combined with
venography when necessary is an essential adjunct to clinical
examination in making this decision.3,4Those patients who do not have an autogenous AVA
option and require a prosthetic AVA remain a challenging
group with poor patency rates compared with autogenous
AVAs. In our own practice, every dialysis access is of su-
preme value because of the low availability of organs for
transplant. This circumstance has driven us to try to im-
prove patency rates by all means available.
Prosthetic AVAs with occlusion occurring at 6 weeks or
earlier have traditionally been thought to be due to techni-
cal factors and were therefore subjected to surgical revision
that was generally associated with a high failure rate.13 The
circumstances that led us to seek alternative means for
re-opening these grafts were that in the past, C-arm fluo-
roscopy, and elective operating room time were less avail-
able. In addition, poor results had previously been obtained
for surgical thrombectomy in prosthetic AVAs, when this
was our primary approach for early occlusion. At the same
time, there were developments in endovascular techniques
that enabled attempts at thrombolysis by angiographic
means in the day care setting.
Endovascular thrombolysis in early graft failure has
traditionally been neglected because of the fear of compli-
cations related to inadequate graft incorporation in the
tissues, but we have performed angiography in recently
constructed grafts later than 1 week postoperatively with-
out significant complications such as hematoma or infec-
tion. Tissue incorporation is sufficient to enable safe needle
puncture for hemodialysis within 1 week after construc-
tion.14 This was the reason we performed thrombolysis at a
minimum of 1 week postoperatively. Of the 20 grafts in the
study, there was no significant puncture site bleeding using
6F or 7F introducer sheaths. Only one procedure was
halted because of extarvasation at the 4 mm tapered end of
the graft arterial anastomosis after thrombectomy and an-
gioplasty using a 5 mm balloon. Performing endovascular
thrombolysis in early graft failure therefore seems to be a
safe procedure.
Seventeen of these 20 grafts that occluded within 6
Fig. Cumulative patency rates for 20 consecutive prosthetic arterio-
venous accesses undergoing thrombolysis bymechanical, chemical, or
combined methods (broken line: standard error 10%).weeks of construction (early failure) were successfully re-
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published data concerning success rates for thrombolysis of
mature grafts that undergo late occlusion.6 Life table anal-
ysis of these grafts shows a 1 year cumulative patency of
68%. Most failures occurred in the first 3 months after the
thrombolysis. No data regarding similar studies for com-
parison with our results could be found in the literature.
One year patency for all occluded prosthetic AVAs (both
early and late occlusions) at our vascular access center is
82%.4
The cause of the occlusion was found to be a technical
problem related to the surgery in only one of the 20
patients with early occlusion when angiography was per-
formed for thrombolysis. Causes for occlusion in the other
patients were hypotension, hypercoagulable states, or ste-
nosis in the proximal draining veins or central veins that
went undetected in the planning stages of access construc-
tion (Table I).
Nine prosthetic AVAs had early occlusion without any
hemodynamically significant lesion contributing to graft
thrombosis. It is well recognized and documented that
prosthetic accesses are inferior to autogenous accesses and
early thromboses are significantly higher in prosthetic ac-
cesses. Blood pressure drops after dialysis may be a major
reason for failure in these grafts. Our own early failure rate
of 15% in prosthetic AVAs prompted us to look for a
solution to this problem. In order to decrease early occlu-
sion rates, we carried out the surgery using systemic intra-
venous heparinization instead of flushing the vein and
artery. This technique may potentially prevent early clot
formation at the anastomosis caused by intimal damage
from the arteriotomy or venotomy and, moreover, mini-
mize endothelial damage by cannula insertion into the
blood vessels. Using this technique, we reduced our early
thrombosis rate to only 7% in this study but could not
eliminate this incidence to the level of 1% to 2% reported in
autogenous AVAs.3
In one of these nine patients, a continuously low blood
pressure developed after surgery from 120 mm Hg to a
level around 90 mm Hg systolic, and the graft occluded
even though the patient was fully anticoagulated. This
patient’s prosthetic access was in the thigh due to superior
vena cava occlusion after multiple previous AVAs and cen-
tral vein catheterizations. Transposition of the great saphe-
nous veinmay have been a better alternative for this patient.
Autogenous AVA is always preferable to prosthetic AVAs,
and vein transposition should be considered as an alterna-
tive.
Two grafts failed early in patients with hypercoagula-
bility states, with insertion of central vein catheters close to
the time of surgery causing central vein thrombosis. Full
anticoagulation postoperatively may be a solution for such
patients if such a state is evident beforehand. In cases where
early occlusion occurs without any obvious anatomical
cause, it would be reasonable to look for a hypercoagulable
state as the cause.
Eleven (55%) of the 20 patients had an obvious lesion
causing the thrombosis (Table II), and in nine of them, itwas treatable by endovascular techniques. The other two
had central occlusions that were not amenable to angio-
plasty and could not be opened. This suggests that the
surgical thrombectomy option may be inappropriate in
many of the patients with early occlusion of prosthetic
AVAs and is actually doomed to failure. Angiography and
thrombolysis seems to be a more suitable strategy than
surgical thrombectomy. Currently intraoperative C-arm
fluoroscopy is well established as an integral part of the
vascular surgery armamentarium, and we believe that any
attempt to perform surgical thrombectomy in prosthetic
AVAs should be combined with angiography and angio-
plasty when necessary.
Some lesions may have been missed at preoperative
assessment because Doppler ultrasound imaging of deep
veins and central veins may be insufficient for diagnosis in
some cases. More liberal use of venography would detect
some of these lesions, specifically the central vein lesions.
There was no arterial cause for occlusion in this series,
suggesting that venous pull back fluoroscopy may be suffi-
cient before surgical or endovascular intervention.
Responsibility for the patient does not end with suc-
cessful thrombolysis. When prosthetic AVA is the required
option for hemodialysis, close surveillance and the conse-
quent aggressive prophylactic interventions, employed in
an overall integrated approach such as a vascular access
management program, can extend and maintain patency
and reduce hospitalization and cost of care.15,16 Mainte-
nance of graft patency requires constant surveillance and
prophylactic interventions. All these patients join our sur-
veillance program and preemptive maintenance angioplasty
is carried out when necessary. It is of note that in this group
of 20 patients, 14 additional procedures were carried out
during surveillance of up to 24 months.
CONCLUSIONS
Most patients in our center with early occlusion of
prosthetic AVA do not occlude because of technical prob-
lems related to surgery. A significant number of patients
have a lesion treatable by endovascular therapy, which can
easily be diagnosed by contrast imaging and that would be
missed at conventional surgery without intraoperative C-
arm fluoroscopy. Endovascular thrombolysis before surgi-
cal thrombectomy for these patients is a safe procedure
whose complications are minor and it is associated with
good patency rates.
The high likelihood that there is no technical problem
in grafts that occlude early should be considered before
attempting surgical revision for an indication that is rarely
present.
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A
Interval (mo)
B
No. at risk
C
No. failed
D
No. with
0-1 20 3 0
1-2 17 1 0
2-3 15 1 1
3-4 13 0 0
4-5 12 0 0
5-6 12 0 0
6-7 12 0 0
7-8 12 1 0
8-9 9 0 1
9-10 7 0 0
10-11 7 0 0
11-12 7 0 0
12-13 7 0 0
13-14 7 0 0
14-15 7 0 0
15-16 7 0 0
16-17 7 0 1
17-18 6 0 0
18-19 6 0 0
19-20 6 0 0
20-21 5 0 1
21-22 5 0 0
22-23 5 0 0
23-24 5 0 0table analysis method
drawn
E
Interval failure
rate
F
Cumulative
patency rate
(%)
G
Standard
error (%)
0.1500 85.00 7.36
0.0588 80.00 8.68
0.0690 74.48 9.71
0.0000 74.48 10.44
0.0000 74.48 10.86
0.0000 74.48 10.86
0.0000 74.48 10.86
0.0833 68.28 11.10
0.0000 68.28 12.82
0.0000 68.28 14.53
0.0000 68.28 14.53
0.0000 68.28 14.53
0.0000 68.28 14.53
0.0000 68.28 14.53
0.0000 68.28 14.53
0.0000 68.28 14.53
0.0000 68.28 14.53
0.0000 68.28 15.70
0.0000 68.28 15.70
0.0000 68.28 15.70
0.0000 68.28 17.20
0.0000 68.28 17.20
0.0000 68.28 17.20
